2019 Executive Sponsors
2019 Associate Sponsors
2019 Technology Sponsors
2019 Exhibitors
2019 Media Partners
2018 Executive Sponsors
2018 Associate Sponsors
2018 Technology Sponsors
2018 Exhibitors
2018 Supporting Sponsor
2018 Soapbox Sponsors
2018 Media Partners
2018 Conference Supporter
Overview
The drug delivery industry is expected to experience robust growth over the next five to ten years, primarily due to the increasing prevalence of chronic conditions and the growing geriatric population. Often, the most complex part of developing a therapeutic is to design an appropriate delivery system for it. The use of drug delivery technologies will continue to rise, as the industry focuses on more cost-effective, targeted, and patient-centered therapies.
The 8th annual Partnership Opportunities in Drug Delivery (PODD) business development event covered the latest advances in drug delivery science, while also providing a meeting place to network and form new partnerships. The PODD event featured a wide range of innovative drug delivery technologies that could potentially improve the delivery of various types of drugs, including proteins, peptides, mRNA therapies, oncology therapeutics, and small molecules.
| Podcast: An Insight into PODD | PODD Celebration |
The 8th annual event was chaired by:
Barbara Lueckel, PhD
Global Business Development Director, Roche Partnering Innovation, Roche
2018 Featured Keynotes included:
Robert Langer, PhD |
Amy Schulman, JD |
Jeffrey Karp, PhD |
Justin Wright, PhD |
2018 Track Chairs:
Nima Akhavein, PhD |
Ulrich Brüggemann |
Mathias Romacker |
Michael Cucolo |
Manuel Sanchez-Felix, PhD |
Ann L Daugherty, PhD |
In addition to presenting cutting-edge technologies and drug delivery solutions, the PODD event also presented expert panel discussions related to the latest challenges and trends in drug delivery today:
- Protein and peptide drug delivery, including non-invasive administration
- High-volume, subcutaneous delivery to optimize delivery and lower healthcare costs
- Gene therapy: the potential of mRNA therapies and vaccines
- Digital health technologies to improve patient adherence and outcomes
- Ophthalmic delivery targeting difficult back of the eye diseases
- Management of the combination product lifecycle: post-market surveillance
- Disruptive new models for advancing development and commercialization of early stage technologies
- Strategic considerations for evaluating and utilizing external delivery technologies
- Patient input on the design and development of next-generation drug delivery systems
 |
 |
 |
PODD attracts more than 350 delegates from drug delivery, pharmaceutical, biotechnology, and medical device companies globally.
Key benefits in 2018 included:
- Hearing from renowned biomedical engineer and entrepreneur, Dr Robert Langer, and highly accomplished investor and biotech executive, Amy Schulman, as they addressed collaboration in drug delivery and what it takes to bring game-changing technologies and therapeutics to the market.
- Learning about the latest drug delivery technology solutions for both small and large molecule drugs, ranging from oral, transdermal, and transmucosal dosage forms to more patient-friendly delivery devices (more than 45 presentations and 50 exhibitors).
- Networking with key decision makers from pharmaceutical, biotechnology, and medical device companies and exploring areas for potential collaboration (more than 8 hours of networking).
- Discovering the current drug delivery needs of pharma and biotech companies and determining what they are looking for in terms of external delivery technologies.
- Understanding the potential impact digital health applications and digitally-enabled drug delivery systems can have on improving patient adherence and overall health outcomes.
The PODD promise:
- To present a strategic-level program for pharma and biotech scientists and business development professionals, with a thorough overview on formulation needs, the latest drug delivery technologies available along with an update on deals and opportunities to improve therapies and extend the life cycle of a drug.
- To provide drug delivery and specialty pharmas with a platform to present their technologies.
- To offer ample networking time and services for one-on-one meetings to establish new business contacts and enhance existing ones.
Sincerely,
Valerie Bowling |
Meredith Sands |
Michelle McDermott |
Meg Gould |
Geeta Bachani |
Bre Bugbee |
Testimonials
"Incredible! Fantastic overview of the industry, recent, partnerships and opportunities for the future. Helpful input on panels, speaker presentations and what's in the pipeline. Great networking opportunities and sharing insights with colleagues. Hard to choose just one area - was all invaluable."
- Kristin King, Rogers Sciences
"Overall very satisfied. Best was networking, coming across new technologies that I did not necessarily have on the radar, and the speaker’s program."
- Gregoire Schwach, Roche
"Was a great conference and getting better every year!"
- Rudy Emmelot, IntraTab Labs
"I have to say PODD was a great opportunity for me. I learned a lot and met great people. Thanks to The Conference Forum."
- Sina Eetezadi, Roche Pharmaceuticals
"Congratulations on a very successful conference! It is a very unique conference and I enjoyed it very much."
- Avinash G. Thombre, PhD, Pfizer Inc
"I was honestly very much impressed by the conference, the set up with presentations and panels and the high level number of executives from the different stakeholders."
- Sven Stegemann, PhD, Geriatric Medicine Society
"This was a great partnering event for us. In addition to our product development services, we have a couple of proprietary technologies that we are promoting. The right group of Directors, Exec Dir, VPs were at the meeting who were all looking for delivery technologies."
- Chris Rhodes, Drug Delivery Experts